In the 160 years since Rudolf Virchow first postulated that neoplasia arises by the same law
that regulates embryonic development, scientists have come to recognize the striking …

The last few years have seen an increasing number of discoveries which collectively
demonstrate that histone and DNA modifying enzyme modulate different stages of …

Using 48,627 samples from the Center for Cancer Genomics and Advanced Therapeutics (C-
CAT), we present a pan-cancer landscape of driver alterations and their clinical actionability …

It is widely assumed that all normal somatic cells can equally perform homologous
recombination (HR) and non-homologous end joining in the DNA damage response (DDR) …

One of the barriers for breast cancer prevention and treatment is our poor understanding of
the dynamic cellular shifts that naturally occur within the breast and how these changes …

Functionally characterizing the genetic alterations that drive pancreatic cancer is a
prerequisite for precision medicine. Here, we perform somatic CRISPR/Cas9 mutagenesis …

Increase in lineage infidelity and/or imbalance is frequently observed around the earliest
stage of breast tumor initiation. In response to disruption of homeostasis, differentiated cells …

The vast number of genomic and molecular alterations in cancer pose a substantial
challenge to uncovering the mechanisms of tumorigenesis and identifying therapeutic …

Tumorigenesis is a multistep process, with oncogenic mutations in a normal cell conferring
clonal advantage as the initial event. However, despite pervasive somatic mutations and …

On 8 December 2022 the organizing committee of the European Network for Breast
Development and Cancer labs (ENBDC) held its fifth annual Think Tank meeting in …